Mid banner advertisement: BDO
RealVNC mid banner careers
Advertisement: CBM
ARM Innovation Hub
Advertisement EY mid banner
Advertisement: Bradfield Centre mid
Advertisement: Lynch Wood Park
RealVNC mid-banner general
Advertisement: Bridge Fibre mid
Barr Ellison Solicitors – commercial property
Advertisement Cambridge China Centre
Advertisement: Cambridge Network
Advertisement: Mogrify mid banner
Advertisement: RSM
20 September, 2018 - 12:11 By Kate Sweeney

New CEO as Domainex expands in US and Europe

Cambridge based drug research services company Domainex has promoted Dr Trevor Perrior to chief executive officer as the business plans further international growth.

Dr Perrior has been director of research and chief scientific officer at Domainex since 2005. The company is based at Chesterford Research Park, one of the UK’s most successful life science environments.

The company has grown significantly during his tenure, delivering numerous development candidates across several therapeutic areas. 

Following his education at the University of Cambridge, Dr Perrior undertook academic research at Cambridge, Oxford and in the US. He then held senior R & D roles in pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, US and Switzerland. 

Dr Perrior is also a scientific consultant to a number of venture capital and charitable organisations and is the Visiting Professor of Medicinal Chemistry at The University of Sussex.

The executive team was recently strengthened by Chris Brown joining as CFO and with Tom Mander as COO continuing to lead business development.

Dr Perrior said: “I believe we are in a strong position to build on our expanding scientific capabilities to serve our global client base. We aim to further increase our business in mainland Europe and in the US where we have just opened two sales offices.”

• PHOTOGRAPH SHOWS: Dr Trevor Perrior

Newsletter Subscription

Stay informed of the latest news and features